CN102762567A - 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类 - Google Patents

作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类 Download PDF

Info

Publication number
CN102762567A
CN102762567A CN2010800643044A CN201080064304A CN102762567A CN 102762567 A CN102762567 A CN 102762567A CN 2010800643044 A CN2010800643044 A CN 2010800643044A CN 201080064304 A CN201080064304 A CN 201080064304A CN 102762567 A CN102762567 A CN 102762567A
Authority
CN
China
Prior art keywords
diazaspiro
undecane
methyl
quinoxalin
ring system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800643044A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴迪格
D·本克
C·贝特斯查尔特
V·乔杜里
S·科泰斯塔
J·H-H·欣里希斯
S·奥夫纳
C·潘迪特
J·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102762567A publication Critical patent/CN102762567A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800643044A 2009-12-21 2010-12-20 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类 Pending CN102762567A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2663/DEL/2009 2009-12-21
IN2663DE2009 2009-12-21
PCT/EP2010/070263 WO2011076747A1 (en) 2009-12-21 2010-12-20 Diaza-spiro[5.5]undecanes as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
CN102762567A true CN102762567A (zh) 2012-10-31

Family

ID=43640117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800643044A Pending CN102762567A (zh) 2009-12-21 2010-12-20 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类

Country Status (9)

Country Link
US (1) US8530648B2 (enExample)
EP (1) EP2516439B1 (enExample)
JP (1) JP2013515033A (enExample)
CN (1) CN102762567A (enExample)
AR (1) AR079553A1 (enExample)
ES (1) ES2459496T3 (enExample)
TW (1) TW201132642A (enExample)
UY (1) UY33125A (enExample)
WO (1) WO2011076747A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831774A (zh) * 2017-02-07 2017-06-13 上海合全药业股份有限公司 一种（6s,7s）‑9‑叔丁氧羰基‑7‑（三氟甲基）‑2,9‑二氮杂螺[5.5]十一烷的合成方法
CN117616030A (zh) * 2021-05-03 2024-02-27 爵士制药爱尔兰有限公司 食欲素受体激动剂及其用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
RU2014136339A (ru) 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
CA2945687A1 (en) * 2014-01-27 2015-07-30 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
KR102738491B1 (ko) 2016-02-12 2024-12-03 아스트라제네카 아베 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) * 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11202106108WA (en) * 2019-01-28 2021-08-30 Suntory Holdings Ltd Composition for competitive inhibition of orexin receptors
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
CA3236104A1 (en) * 2021-10-27 2023-05-04 Hugh Y. Zhu Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
WO2023081094A1 (en) * 2021-11-04 2023-05-11 University Of Washington Novel spirocyclic compounds as klhdc2 ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002986A2 (en) * 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
WO2007025069A2 (en) * 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2007058322A1 (ja) * 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002986A2 (en) * 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
WO2007025069A2 (en) * 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIAQIANG CAI ET AL: "Antagonists of the orexin receptors", 《EXPERT.OPIN.THER.PATENTS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831774A (zh) * 2017-02-07 2017-06-13 上海合全药业股份有限公司 一种（6s,7s）‑9‑叔丁氧羰基‑7‑（三氟甲基）‑2,9‑二氮杂螺[5.5]十一烷的合成方法
CN117616030A (zh) * 2021-05-03 2024-02-27 爵士制药爱尔兰有限公司 食欲素受体激动剂及其用途

Also Published As

Publication number Publication date
EP2516439B1 (en) 2014-01-22
US8530648B2 (en) 2013-09-10
UY33125A (es) 2011-07-29
EP2516439A1 (en) 2012-10-31
TW201132642A (en) 2011-10-01
ES2459496T3 (es) 2014-05-09
JP2013515033A (ja) 2013-05-02
US20120264748A1 (en) 2012-10-18
WO2011076747A1 (en) 2011-06-30
AR079553A1 (es) 2012-02-01

Similar Documents

Publication Publication Date Title
CN102762567A (zh) 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
KR102449652B1 (ko) Rock의 억제제로서의 스피로-융합 시클릭 우레아
EP2516437B1 (en) Disubstituted heteroaryl-fused pyridines
CN105308048B (zh) 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN103180326B (zh) 杂环化合物及其用途
CN104936955B (zh) 噻二唑类似物以及治疗与smn缺乏相关的病症的方法
EP3362442B1 (en) 2,4-dihydroxy-nicotinamides as apj agonists
KR20200083543A (ko) 디아자스피로 rock 억제제
KR20190117006A (ko) 키나제 억제제로서의 아미노트리아졸로피리딘
CN107108566B (zh) 取代的2-氮杂双环化合物以及它们作为食欲素受体调节剂的用途
US20120165331A1 (en) Di/tri-aza-spiro-C9-C11alkanes
WO2018089353A1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
AU2013329097B2 (en) Urea and amide derivatives of aminoalkylpiperazines and use thereof
CN110072850A (zh) 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
WO2021247971A1 (en) Inhibitors of fibroblast growth factor receptor kinases
US20250011288A1 (en) Rxfp1 agonists
EP4561552A2 (en) Cdk2 inhibitors and methods of using the same
US20120101110A1 (en) Diaza-spiro[5.5]undecanes
US20230183237A1 (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
EP3652157B1 (en) 1,3-diaza-spiro-[3.4]-octane derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031